Radioembolization for Liver Cancer

Palo Alto (17 mi)

Armeen Mahvash | MD Anderson Cancer Center

Overseen byArmeen Mahvash, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?This clinical trial studies the side effects and best way to perform yttrium Y-90 radioembolization in treating patients with liver cancer that has spread to other places in the body (metastatic). Yttrium Y-90 radioembolization is a therapy that injects radioactive microspheres directly into an artery that feeds liver tumors to cut off their blood supply. Performing yttrium Y-90 radioembolization in a single session may make treatment faster, minimize patient travel, and decrease the overall cost of the procedure.

Eligibility Criteria

This trial is for patients with liver cancer that has spread, who can understand and sign a consent form. It's suitable for those eligible for standard Y90 radioembolization treatment but not for patients where the cancer affects more than half of the liver.

Treatment Details

The study tests yttrium Y-90 radioembolization, which involves injecting radioactive particles into an artery to block blood flow to liver tumors. The focus is on doing this in one session to see if it's effective and more efficient.

1Treatment groups

Experimental Treatment

Group I: Treatment (angiography, yttrium Y-90 radioembolization)Experimental Treatment7 Interventions

The first 2 patients enrolled receive standard of care diagnostic and treatment during 2 visits for approximately 6 hours each within 2-4 weeks. During the first visit, patients undergo diagnostic angiography with embolization of potential hepatoenteric collaterals, receive technetium Tc-99m albumin aggregated as a surrogate to the therapy microspheres via catheter, and undergo planar imaging. During the second visit, patients undergo a second angiography and receive yttrium Y 90 resin microspheres via arterial microcatheter. Patients then undergo single-photon emission computed tomography-computed tomography (SPECT-CT) Bremsstrahlung imaging. All subsequent patients enrolled undergo the same previously described diagnostic and treatment during 1 visit over about 8 hours.